Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).
NCT05946330 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2023-07-19
Summary
The goal of this randomized clinical trial with adults is to discuss the effectiveness of the nutritionist's educational interventions in users diagnosed with NAFLD, compared to the usual medical follow-up of users treated at the Hepatic Steatosis Ambulatory of the Complexo Hospital de Clinicas of the Federal University of Paraná (CHCUFPR) in adults diagnosed with liver disease. The sample will consist of patients routinely monitored at the Hepatic Steatosis outpatient clinic diagnosed with non-alcoholic fatty liver disease. Patients allocated in the study will be randomized 1:1 and followed up for one (1) year, intervention group (IG) with nutritionist consultations, nutritional diagnosis and educational intervention with agreement on individual goals. Patients in the Control Group (CG) will maintain the usual outpatient care. Participants will have clinical, anthropometric and sociodemographic data collected and food consumption data will be carried out during the nutrition consultations, as well as the application of the NLS-Br Nutritional Literacy questionnaire to verify literacy. During the nutrition consultation, a 24-hour recall will be carried out to collect information on food consumption. They will also be carried out as monthly telephone contacts or messages via instant messaging application, to solve the doubts of the participants and notify them of upcoming meetings, and subsequent comparison of the LN in the target population. All interventions will be recorded in specific instruments for this purpose.
Researchers will compare intervention group (IG) and Control Group (CG) and to see the effects of nutritional intervention. The expected primary outcome will be weight loss of 5% to 10% of the initial weight and the secondary outcomes will be: reduction in abdominal circumference and body mass index, and improvement in the levels of liver transaminases. Data will be analyzed with descriptive and inferential statistics.
Conditions
- Steatohepatitis, Nonalcoholic
- Steatosis
- Liver Diseases
- Steatohepatitis
Interventions
- BEHAVIORAL
-
NUTRITIONAL EDUCATIONAL INTERVENTION IN FATTY LIVER DISEASE NON-ALCOHOLIC (NAFLD).
The intervention group will receive educational actions in individual nutrition with nutrition consultation (in person at the beginning and at 180 days of the intervention and phone calls and text messages at 30, 60, 90, 120 and 150, 240 and 300 days of follow-up
Sponsors & Collaborators
-
Universidade Federal do Paraná
lead OTHER
Principal Investigators
-
Maria F Mantovani, Dr · Universidade Federal do Paraná
-
Maria E Schieferdecker, Dr · Universidade Federal do Paraná
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-22
- Primary Completion
- 2023-06-23
- Completion
- 2024-07-31
Countries
- Brazil
Study Locations
More Related Trials
-
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
NCT05065593 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment
NCT01987310 ·Status: WITHDRAWN ·Phase: NA
-
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
NCT02369536 ·Status: COMPLETED ·Phase: NA
-
Ambulatory Liver Fat Monitoring in Patients With Non-alcoholic Fatty Liver Disease
NCT05754385 ·Status: COMPLETED ·Phase: NA
-
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
NCT06308757 ·Status: RECRUITING ·Phase: NA
-
6-week Safety and PD Study in Adults With NAFLD
NCT03256526 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment
NCT05694923 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Nutritional Therapy With High Methionine Content in the Treatment of NAFLD
NCT04450875 ·Status: COMPLETED ·Phase: NA
-
Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease
NCT04132440 ·Status: ACTIVE_NOT_RECRUITING
-
Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis
NCT01950884 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
NCT05768334 ·Status: COMPLETED ·Phase: PHASE3
-
Smartphone App for Non-alcoholic Fatty Liver Disease
NCT05180760 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Efficacy of N-Acetylcysteine in Improving/Normalizing ALT & AST in Patients of NAFLD
NCT05576428 ·Status: UNKNOWN ·Phase: NA
-
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
NCT05364684 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.
NCT04579874 ·Status: COMPLETED ·Phase: NA
-
Probiotics in NASH Patients - PROBILIVER TRIAL
NCT03467282 ·Status: UNKNOWN ·Phase: NA
-
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
NCT02077374 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Sohag University Employees
NCT06536933 ·Status: NOT_YET_RECRUITING
-
Pentoxifylline in Patients With Nonalcoholic Steatohepatitis
NCT00590161 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects
NCT05930093 ·Status: RECRUITING ·Phase: NA
-
A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
NCT03350165 ·Status: COMPLETED ·Phase: PHASE2
-
Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)
NCT00596934 ·Status: COMPLETED ·Phase: PHASE2
-
RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease
NCT03365531 ·Status: TERMINATED ·Phase: NA
-
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
NCT03776175 ·Status: COMPLETED ·Phase: PHASE2
-
Different Doses of ZED1227 vs. Placebo in NAFLD
NCT05305599 ·Status: COMPLETED ·Phase: PHASE2